专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09546155B2 Aromatic heterocyclic compound 有权
标题翻译：芳香杂环化合物
公开(公告)号：US09546155B2
公开(公告)日：2017-01-17
申请号：US14407282
申请日：2013-06-14
申请人： MITSUBISHI TANABE PHARMA CORPORATION
发明人： Kunio Saruta , Norimitsu Hayashi , Osamu Sakurai , Hiroaki Sawamoto , Eri Ooboki
IPC分类号： C07D401/04 , C07D401/14 , C07D413/14 , C07D401/10 , C07D409/14 , C07D417/14 , C07D249/08 , C07D405/14 , C07D249/14
CPC分类号： C07D401/14 , C07D249/08 , C07D249/14 , C07D401/04 , C07D401/10 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
摘要： The compound represented by the general formula: wherein ring A is benzene which may be substituted and the like; ring B is benzene which may be substituted and the like; X is a single bond and the like; Y is alkyl which may be substituted and the like; Z is CR1 or nitrogen atom; R1 is hydrogen and the like; R2 is alkyl which may be substituted and the like or a pharmaceutically acceptable salt thereof is useful as a prevention/treatment agent of obesity, diabetes, and the like.
摘要翻译：由通式表示的化合物：其中环A是可被取代的苯等; 环B是可以被取代的苯等; X是单键等; Y是可被取代的烷基等; Z是CR1或氮原子; R1是氢等; R2是可以被取代的烷基等，或其药学上可接受的盐可用作肥胖，糖尿病等的预防/治疗剂。

2. 发明授权

US08778628B2 Arylalkylamine compound and process for preparing the same 有权
标题翻译：芳烷基胺化合物及其制备方法
公开(公告)号：US08778628B2
公开(公告)日：2014-07-15
申请号：US13919829
申请日：2013-06-17
申请人： Mitsubishi Tanabe Pharma Corporation
发明人： Hiroshi Miyazaki , Junko Okabe , Kosuke Yasuda , Iwao Takamuro , Osamu Sakurai , Tetsuya Yanagida , Yutaka Hisada
IPC分类号： C07D205/04 , C07D207/14 , C07D207/16 , C07D207/27 , C07D207/327 , C07D207/335 , C07D207/34 , C07D211/56 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D403/06 , C07D403/10 , C07D405/12 , C07D409/06 , C07D409/12 , C07D417/04 , C07D417/06
CPC分类号： C07D207/14 , C07D205/04 , C07D207/16 , C07D207/27 , C07D207/327 , C07D207/335 , C07D207/34 , C07D211/56 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D403/06 , C07D403/10 , C07D405/12 , C07D409/06 , C07D409/12 , C07D417/04 , C07D417/06 , C07H17/02
摘要： An arylalkylamine compound is represented by the following formula [I-e] or a pharmaceutically acceptable salt thereof.
摘要翻译：芳基烷基胺化合物由下式[I-e]表示或其药学上可接受的盐。

3. 发明授权

US09975871B2 Continuous arycyclic compound 有权
公开(公告)号：US09975871B2
公开(公告)日：2018-05-22
申请号：US15050154
申请日：2016-02-22
申请人： MITSUBISHI TANABE PHARMA CORPORATION
发明人： Osamu Sakurai , Kunio Saruta , Norimitsu Hayashi , Takashi Goi , Kenji Morokuma , Hidekazu Tsujishima , Hiroaki Sawamoto , Hiroaki Shitama , Ritsuo Imashiro
IPC分类号： C07D401/04 , C07D233/64 , C07D401/10 , C07D401/14 , C07D403/04 , C07D403/10 , C07D405/14
CPC分类号： C07D401/04 , C07D233/64 , C07D401/10 , C07D401/14 , C07D403/04 , C07D403/10 , C07D405/14
摘要： This is to provide a continuous arycyclic compound having a DGAT1 inhibitory activity, and useful for prophylaxis and/or treatment of obesity or hyperlipidemia caused by obesity, hypertriglyceridemia, lipid metabolism disorder, fatty liver, hypertension, arteriosclerosis, diabetes, etc., as well as to provide a DGAT1 inhibitor comprising the continuous arycyclic compound or a pharmaceutically acceptable salt thereof as an effective ingredient. Disclosed is the continuous arycyclic compound is represented by the formula: wherein the substituents in the formula are the same as defined in the specification, or a pharmaceutically acceptable salt thereof.

4. 发明授权

US08759387B2 Arylalkylamine compound and process for preparing the same 有权
标题翻译：芳烷基胺化合物及其制备方法
公开(公告)号：US08759387B2
公开(公告)日：2014-06-24
申请号：US13717448
申请日：2012-12-17
申请人： Mitsubishi Tanabe Pharma Corporation
发明人： Hiroshi Miyazaki , Junko Okabe , Kosuke Yasuda , Iwao Takamuro , Osamu Sakurai , Tetsuya Yanagida , Yutaka Hisada
IPC分类号： A61K31/40 , C07D295/22
CPC分类号： C07D207/14 , C07D205/04 , C07D207/16 , C07D207/27 , C07D207/327 , C07D207/335 , C07D207/34 , C07D211/56 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D403/06 , C07D403/10 , C07D405/12 , C07D409/06 , C07D409/12 , C07D417/04 , C07D417/06 , C07H17/02
摘要： The present invention relates to an arylalkylamine compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, a process for preparing the same, and use of the above-mentioned compound as an activating compound (CaSR agonist) of a Ca sensing receptor, a pharmaceutical composition containing the above-mentioned compound as an effective ingredient, etc. The symbols in the formula represent the following meanings: Ar: optionally substituted aryl or optionally substituted heteroaryl here, the cyclic portion of the heteroaryl is bicyclic heterocyclic ring in which 5- to 6-membered monocyclic heterocyclic ring containing 1 or 2 hetero atom(s) and benzene ring are fused; R1: a group selected from the group consisting of optionally substituted cyclic hydrocarbon group, and optionally substituted heterocyclic group; n: an integer of 1 to 3; X: single bonding arm, —CH2—, —CO—, —(CH2)m—CO—, —CH(R2)—CO—, —(CH2)p—Y—(C(R3)(R4))q—CO—, —NH—CO— or —N(R5)—CO—; in the above-mentioned respective definitions of the X, the bonding arm described at the left end represents a bond with R1; m is an integer of 1 to 3; p is an integer of 0 to 2; q is an integer of 0 to 2; Y: —O— or —SO2—; R2: phenyl or lower alkyl; R3, R4: each independently represents hydrogen atom or lower alkyl; R5: lower alkyl; provided that the ring portion of the group represented by R1 is neither naphthylidine nor partially saturated group thereof, and, when X is —CH2— or —CO—, R1 is not naphthyl.
摘要翻译：本发明涉及由下式[I]表示的芳基烷基胺化合物或其药学上可接受的盐，其制备方法，以及使用上述化合物作为Ca感应的活化化合物（CaSR激动剂）受体，含有上述化合物作为有效成分的药物组合物等。式中的符号表示如下含义：Ar：任选取代的芳基或任选取代的杂芳基，杂芳基的环状部分为双环杂环含有1或2个杂原子和苯环的5-至6-元单环杂环稠合; R1：选自任选取代的环状烃基和任选取代的杂环基的基团; n：1〜3的整数; X：单键，-CH 2 - ， - CO - ， - （CH 2）m -CO-， - CH（R 2）-CO-， - （CH 2）p-Y-（C（R 3） -CO - ， - NH-CO-或-N（R 5）-CO-; 在X的上述各个定义中，左端描述的接合臂表示与R1的键; m为1〜3的整数。 p为0〜2的整数。 q为0〜2的整数; Y：-O-或-SO 2 - ; R2：苯基或低级烷基; R3，R4各自独立地表示氢原子或低级烷基; R5：低级烷基; 条件是由R1表示的基团的环部分既不是萘基也不是部分饱和的基团，并且当X是-CH 2 - 或-CO-时，R 1不是萘基。

5. 发明授权

US10308636B2 Aromatic heterocyclic compound 有权
公开(公告)号：US10308636B2
公开(公告)日：2019-06-04
申请号：US15250379
申请日：2016-08-29
申请人： MITSUBISHI TANABE PHARMA CORPORATION
发明人： Kunio Saruta , Norimitsu Hayashi , Osamu Sakurai , Hiroaki Sawamoto , Eri Ooboki
IPC分类号： C07D401/10 , C07D401/14 , C07D413/14 , C07D401/04 , C07D409/14 , C07D417/14 , C07D249/08 , C07D405/14 , C07D249/14
摘要： The compound represented by the general formula: wherein ring A is benzene which may be substituted and the like; ring B is benzene which may be substituted and the like; X is a single bond and the like; Y is alkyl which may be substituted and the like; Z is CR1 or nitrogen atom; R1 is hydrogen and the like; R2 is alkyl which may be substituted and the like or a pharmaceutically acceptable salt thereof is useful as a prevention/treatment agent of obesity, diabetes, and the like.

6. 发明申请

US20150158844A1 AROMATIC HETEROCYCLIC COMPOUND 有权
标题翻译：芳香杂环化合物
公开(公告)号：US20150158844A1
公开(公告)日：2015-06-11
申请号：US14407282
申请日：2013-06-14
申请人： MITSUBISHI TANABE PHARMA CORPORATION
发明人： Kunio Saruta , Norimitsu Hayashi , Osamu Sakurai , Hiroaki Sawamoto , Eri Ooboki
IPC分类号： C07D401/14 , C07D405/14 , C07D401/10 , C07D401/04 , C07D413/14
CPC分类号： C07D401/14 , C07D249/08 , C07D249/14 , C07D401/04 , C07D401/10 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
摘要： The compound represented by the general formula: wherein ring A is benzene which may be substituted and the like; ring B is benzene which may be substituted and the like; X is a single bond and the like; Y is alkyl which may be substituted and the like; Z is CR1 or nitrogen atom; R1 is hydrogen and the like; R2 is alkyl which may be substituted and the like or a pharmaceutically acceptable salt thereof is useful as a prevention/treatment agent of obesity, diabetes, and the like.
摘要翻译：由通式表示的化合物：其中环A是可被取代的苯等; 环B是可以被取代的苯等; X是单键等; Y是可被取代的烷基等; Z是CR1或氮原子; R1是氢等; R2是可以被取代的烷基等，或其药学上可接受的盐可用作肥胖，糖尿病等的预防/治疗剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式